| 0 |
26/09/201910:17 AM |
|
Annual Report to Shareholders 66 pages 2.3MB |
| 1 |
26/09/201910:10 AM |
|
Appendix 4G 12 pages 221.5KB |
| 2 |
26/09/201910:08 AM |
|
Corporate Governance Statement 8 pages 301.9KB |
| 3 |
26/09/201910:07 AM |
|
Section 708 Certificate 2 pages 153.3KB |
| 4 |
26/09/201910:05 AM |
|
Section 708 Certificate 11 pages 312.8KB |
| 5 |
26/09/201910:04 AM |
|
Appendix 3B 12 pages 454.8KB |
| 6 |
24/09/20192:30 PM |
|
Amended/Departure of Dr Van Wyk 2 pages 147.2KB |
| 7 |
24/09/20192:15 PM |
|
Departure of Dr Wan Wyk 2 pages 147.1KB |
| 8 |
17/09/20191:08 PM |
 |
Veyonda and Radiotherapy Profiled at Key Oncology Meeting 4 pages 203.2KB |
| 9 |
16/09/201912:32 PM |
|
Results of Meeting 3 pages 194.9KB |
| 10 |
16/09/20199:11 AM |
|
NOX EGM Chairman's Address and Presentation 29 pages 739.0KB |
| 11 |
12/09/201912:20 PM |
|
CHANGE OF DIRECTOR'S INTEREST NOTICE - GK 4 pages 218.0KB |
| 12 |
10/09/201910:47 AM |
|
CHANGE OF DIRECTOR'S INTEREST NOTICE - GK 4 pages 218.1KB |
| 13 |
29/08/20197:13 PM |
|
Appendix 4E and Audited Financial Statements FY19 53 pages 1.8MB |
| 14 |
28/08/20197:14 PM |
|
Addendum to Notice of Extraordinary General Meeting 5 pages 205.8KB |
| 15 |
28/08/20199:26 AM |
|
More Evidence that Veyonda Enhances RT in Prostate Cancer 6 pages 222.1KB |
| 16 |
23/08/20193:13 PM |
|
NOX Receives FY19 Federal Government R&D Tax Rebate 2 pages 155.6KB |
| 17 |
23/08/20193:06 PM |
|
Appendix 3B 12 pages 388.3KB |
| 18 |
23/08/20193:05 PM |
|
Cleansing Statement 2 pages 160.1KB |
| 19 |
21/08/201910:55 AM |
|
Pre-Clinical Evidence Confirms Veyonda Abscopal Effect 3 pages 221.7KB |
| 20 |
15/08/20198:19 AM |
|
Lead Manager Appointed for Proposed Nyrada IPO 2 pages 266.5KB |
| 21 |
12/08/20198:46 AM |
|
Notice of Extraordinary General Meeting/Proxy Form 27 pages 655.3KB |
| 22 |
09/08/201911:11 AM |
|
Noxopharm Corporate Update Interview 2 pages 223.8KB |
| 23 |
07/08/20198:41 AM |
|
Noxopharm August 2019 Corporate Presentation 41 pages 19.5MB |
| 24 |
02/08/201912:25 PM |
|
NOX Releases Initial Newsletter for Nyrada Subsidiary 10 pages 3.2MB |
| 25 |
29/07/20198:59 AM |
|
Appendix 4C - Quarterly 12 pages 425.3KB |
| 26 |
25/07/20191:31 PM |
|
Appendix 3B 12 pages 394.5KB |
| 27 |
25/07/20191:31 PM |
|
Section 708 Certificate 7 pages 295.0KB |
| 28 |
23/07/201912:44 PM |
|
Appendix 3B 12 pages 394.1KB |
| 29 |
23/07/201912:42 PM |
|
Section 708 Certificate 1 page 142.7KB |
| 30 |
19/07/20194:05 PM |
|
Initial Director's Interest Notice 2 pages 130.2KB |
| 31 |
19/07/20194:03 PM |
|
Final Director's Interest Notice 2 pages 195.7KB |
| 32 |
19/07/20199:51 AM |
|
NOX Announces AU$26 Million Funding Facility 4 pages 290.6KB |
| 33 |
17/07/201910:38 AM |
|
NOX Releases Latest Newsletter 12 pages 2.8MB |
| 34 |
16/07/20199:51 AM |
|
Board Changes Ahead of Corporate Growth 4 pages 344.5KB |
| 35 |
02/07/20199:59 AM |
|
SNMMI 2019 Conference LuPIN Presentation Released 2 pages 304.8KB |
| 36 |
26/06/20199:25 AM |
|
Conference Hears of Positive Interim Data from LuPIN Trial 4 pages 369.6KB |
| 37 |
07/06/201910:43 AM |
|
NOX Subsidiary, Nyrada Inc, Receives R&D Rebate 2 pages 167.0KB |
| 38 |
06/06/20199:14 AM |
|
Noxopharm Corporate Presentation June 2019 25 pages 7.4MB |
| 39 |
30/05/20198:41 AM |
|
DARRT-1 Study Fully Enrolled 3 pages 167.5KB |
| 40 |
23/05/20198:33 AM |
|
Promising Data Leads to Expansion of LuPIN Trial 3 pages 169.4KB |
| 41 |
20/05/201910:27 AM |
|
LuPIN Trial Demonstrates High Rates of Response 4 pages 207.1KB |
| 42 |
08/05/20199:23 AM |
|
Change of Director's Interest Notice - GK 4 pages 152.1KB |
| 43 |
08/05/20199:18 AM |
|
Appendix 3B 12 pages 387.9KB |
| 44 |
02/05/20199:35 AM |
|
DARRT Treatment Has Lasting Disease Control at Six Months 4 pages 199.9KB |
| 45 |
29/04/20199:21 AM |
|
Veyonda and Immuno-Oncology Effect Explained 3 pages 201.5KB |
| 46 |
26/04/20199:01 AM |
|
Appendix 4C - Quarterly 9 pages 433.3KB |
| 47 |
23/04/20198:49 AM |
|
Change in Noxopharm Limited Board Structure 2 pages 186.2KB |
| 48 |
16/04/20199:54 AM |
|
Idronoxil Confirmed as New Immuno-Oncology Drug 2 pages 212.7KB |
| 49 |
10/04/20198:22 AM |
|
Veyonda Chemotherapy Enhancement Program to be Expanded 3 pages 274.8KB |
| 50 |
08/04/201911:32 AM |
|
Securities to be released from Voluntary Escrow 1 page 125.0KB |
| 51 |
05/04/201912:19 PM |
|
Updated Top 20 shareholder List 3 pages 178.3KB |
| 52 |
25/03/201911:00 AM |
|
Appendix 3B 11 pages 399.9KB |
| 53 |
25/03/201910:58 AM |
|
Section 708 Certificate 1 page 142.3KB |
| 54 |
21/03/20194:42 PM |
|
Becoming a substantial holder 4 pages 141.4KB |
| 55 |
19/03/201912:06 PM |
|
KZA: Kazia sells stake in Noxopharm 1 page 148.7KB |
| 56 |
06/03/20198:33 AM |
|
NOX provides update to Nyrada Note Holders 7 pages 332.1KB |
| 57 |
05/03/201911:59 AM |
|
New Corporate Presentation Released 25 pages 13.4MB |
| 58 |
21/02/20198:46 AM |
|
Noxopharm to expedite Veyonda Clinical Program 4 pages 174.8KB |
| 59 |
21/02/20198:41 AM |
|
Appendix 4D and Half Year Accounts 19 pages 412.9KB |
| 60 |
14/02/20198:53 AM |
|
Change of Director's Interest Notice - GK 4 pages 216.3KB |
| 61 |
08/02/20194:29 PM |
|
Updated Share Trading Policy 6 pages 227.5KB |
| 62 |
06/02/201911:06 AM |
|
FNN interview with Nox Chief Medical Officer on Interim Data 2 pages 157.8KB |
| 63 |
06/02/20198:45 AM |
|
Veyonda and Radiotherapy Delivers Clinical Benefits 5 pages 741.4KB |
| 64 |
01/02/20193:06 PM |
|
Appendix 3B 11 pages 400.8KB |
| 65 |
29/01/20199:46 AM |
|
Appendix 4C - Quarterly 10 pages 461.3KB |
| 66 |
14/01/201910:24 AM |
|
Principal Investigator Discusses LuPIN-1 Study 3 pages 168.2KB |
